Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
Yükleniyor...
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Abstract Background Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed that CMA improves the AD-associated histological parameters in the animals. CMA promotes mitochondrial fatty acid uptake from the cytosol, facilitates fatty acid oxidation in the mitochondria, and alleviates oxidative stress. Methods Here, we designed a randomised, double-blinded, placebo-controlled phase-II clinical trial and studied the efect of CMA administration on the global metabolism of AD patients. One-dose CMA included 12.35 g L-serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl-L-cysteine (12.75%), and 3.73 g L-carnitine tartrate (18.65%). AD patients received one dose of CMA or placebo daily during the frst 28 days and twice daily between day 28 and day 84. The primary endpoint was the diference in the cognitive function and daily living activity scores between the placebo and the treatment arms. The secondary aim of this study was to evaluate the safety and tolerability of CMA. A comprehensive plasma metabolome and proteome analysis was also performed to evaluate the efcacy of the CMA in AD patients. Results We showed a signifcant decrease of AD Assessment Scale-cognitive subscale (ADAS-Cog) score on day 84 vs day 0 (P=0.00001, 29% improvement) in the CMA group. Moreover, there was a signifcant decline (P=0.0073) in ADAS-Cog scores (improvement of cognitive functions) in the CMA compared to the placebo group in patients with higher ADAS-Cog scores. Improved cognitive functions in AD patients were supported by the relevant alterations in the hippocampal volumes and cortical thickness based on imaging analysis. Moreover, the plasma levels of
Açıklama
Anahtar Kelimeler
Alzheimer’s disease, Combined metabolic activators, Multi-omics, Systems biology, Systems medicine
Kaynak
Translational Neurodegeneration
WoS Q Değeri
Scopus Q Değeri
Q1
Cilt
12
Sayı
1
Künye
Bağlantı
https://hdl.handle.net/20.500.12868/2298
https://www.scopus.com/record/display.uri?eid=2-s2.0-85146871450&origin=resultslist&sort=plf-f&src=s&sid=4c68d1b3b1ca5114c6f907d7c387d6fd&sot=b&sdt=b&s=TITLE-ABS-KEY%28Combined+metabolic+activators+improve+cognitive+functions+in+Alzheimer%E2%80%99s+disease+patients%3A+a+randomised%2C+double-blinded%2C+placebo-controlled+phase-II+trial%29&sl=169&sessionSearchId=4c68d1b3b1ca5114c6f907d7c387d6fd&relpos=0
https://www.scopus.com/record/display.uri?eid=2-s2.0-85146871450&origin=resultslist&sort=plf-f&src=s&sid=4c68d1b3b1ca5114c6f907d7c387d6fd&sot=b&sdt=b&s=TITLE-ABS-KEY%28Combined+metabolic+activators+improve+cognitive+functions+in+Alzheimer%E2%80%99s+disease+patients%3A+a+randomised%2C+double-blinded%2C+placebo-controlled+phase-II+trial%29&sl=169&sessionSearchId=4c68d1b3b1ca5114c6f907d7c387d6fd&relpos=0
